282 related articles for article (PubMed ID: 28864644)
1. Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort.
Sharma N; Putman MS; Vij R; Strek ME; Dua A
J Rheumatol; 2017 Nov; 44(11):1612-1618. PubMed ID: 28864644
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis.
Kurita T; Yasuda S; Oba K; Odani T; Kono M; Otomo K; Fujieda Y; Oku K; Bohgaki T; Amengual O; Horita T; Atsumi T
Rheumatology (Oxford); 2015 Jan; 54(1):39-44. PubMed ID: 24764266
[TBL] [Abstract][Full Text] [Related]
3. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus.
Wilkes MR; Sereika SM; Fertig N; Lucas MR; Oddis CV
Arthritis Rheum; 2005 Aug; 52(8):2439-46. PubMed ID: 16052580
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease.
Labirua-Iturburu A; Selva-O'Callaghan A; Martínez-Gómez X; Trallero-Araguás E; Labrador-Horrillo M; Vilardell-Tarrés M
Clin Exp Rheumatol; 2013; 31(3):436-9. PubMed ID: 23465087
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.
Huapaya JA; Silhan L; Pinal-Fernandez I; Casal-Dominguez M; Johnson C; Albayda J; Paik JJ; Sanyal A; Mammen AL; Christopher-Stine L; Danoff SK
Chest; 2019 Nov; 156(5):896-906. PubMed ID: 31238042
[TBL] [Abstract][Full Text] [Related]
6. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.
Mimori T; Nakashima R; Hosono Y
Curr Rheumatol Rep; 2012 Jun; 14(3):264-74. PubMed ID: 22367479
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of HRCT in myositis-associated interstitial lung disease.
Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Aihara K; Ikezoe K; Watanabe K; Taguchi Y; Hatta K; Oga T; Chin K; Nagai S; Mimori T; Mishima M
Respir Med; 2013 May; 107(5):745-52. PubMed ID: 23485097
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review.
Ge Y; Zhou H; Shi J; Ye B; Peng Q; Lu X; Wang G
Clin Rheumatol; 2015 Dec; 34(12):2097-103. PubMed ID: 26328518
[TBL] [Abstract][Full Text] [Related]
10. Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease.
Witt LJ; Demchuk C; Curran JJ; Strek ME
Pulm Pharmacol Ther; 2016 Feb; 36():46-52. PubMed ID: 26762710
[TBL] [Abstract][Full Text] [Related]
11. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis.
Ochi S; Nanki T; Takada K; Suzuki F; Komano Y; Kubota T; Miyasaka N
Clin Exp Rheumatol; 2005; 23(5):707-10. PubMed ID: 16173253
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease.
Cavagna L; Caporali R; Abdì-Alì L; Dore R; Meloni F; Montecucco C
J Rheumatol; 2013 Apr; 40(4):484-92. PubMed ID: 23418387
[TBL] [Abstract][Full Text] [Related]
13. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis.
Fujisawa T; Suda T; Nakamura Y; Enomoto N; Ide K; Toyoshima M; Uchiyama H; Tamura R; Ida M; Yagi T; Yasuda K; Genma H; Hayakawa H; Chida K; Nakamura H
J Rheumatol; 2005 Jan; 32(1):58-64. PubMed ID: 15630726
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease.
Johnson C; Pinal-Fernandez I; Parikh R; Paik J; Albayda J; Mammen AL; Christopher-Stine L; Danoff S
Lung; 2016 Oct; 194(5):733-7. PubMed ID: 27166633
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis.
Yokoyama Y; Furuta S; Ikeda K; Hirose K; Nakajima H
Mod Rheumatol; 2015; 25(6):888-92. PubMed ID: 25775144
[TBL] [Abstract][Full Text] [Related]
16. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis.
Kurita T; Yasuda S; Amengual O; Atsumi T
Lupus; 2015 Jan; 24(1):3-9. PubMed ID: 25297551
[TBL] [Abstract][Full Text] [Related]
18. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus.
Yamano Y; Taniguchi H; Kondoh Y; Ando M; Kataoka K; Furukawa T; Johkoh T; Fukuoka J; Sakamoto K; Hasegawa Y
Respirology; 2018 Nov; 23(11):1041-1048. PubMed ID: 30011421
[TBL] [Abstract][Full Text] [Related]
19. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis.
Mira-Avendano IC; Parambil JG; Yadav R; Arrossi V; Xu M; Chapman JT; Culver DA
Respir Med; 2013 Jun; 107(6):890-6. PubMed ID: 23517887
[TBL] [Abstract][Full Text] [Related]
20. [Idiopathic inflammatory myopathies from the viewpoint of rheumatologists].
Gono T; Katsumata Y; Kawaguchi Y
Brain Nerve; 2013 Nov; 65(11):1275-82. PubMed ID: 24200605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
